An open-label, non-randomized study investigating the safety and efficacy of smallpox vaccine, LC16, as post-exposure prophylaxis for mpox

• Váldodahkkit: Noriko Tomita (Dahkki), Junko Terada-Hirashima (Dahkki), Yukari Uemura (Dahkki), Yosuke Shimizu (Dahkki), Haruka Iwasaki (Dahkki), Rina Yano (Dahkki), Tetsuya Suzuki (Dahkki), Sho Saito (Dahkki), Nobumasa Okumura (Dahkki), Wataru Sugiura (Dahkki), Norio Ohmagari (Dahkki), Mugen Ujiie (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Taylor & Francis Group, 2023-08-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Mpox is an acute exanthematous disease caused by the monkeypox virus. Since May 2022, it has spread as a community-acquired infection, mainly in Europe and the United States, and urgent measures to prevent this infection were also required in Japan. In this study, we investigated the post-exposure p...